Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Celularity, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2017-09-01

Employees: 225

Market Cap: $66.1M

Website: http://www.celularity.com

Clinical Trials

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Phase 1

Withdrawn

Conditions: Astrocytoma, Grade IV
Glioblastoma Multiforme
Glioblastoma
Giant Cell Glioblastoma

First Posted Date: 2022-02-01

Last Posted Date: 2023-02-16

Lead Sponsor: Celularity Incorporated

Registration Number: NCT05218408

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1

Terminated

Conditions: Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions: Biological: CYNK-101
Drug: Pembrolizumab
Drug: Trastuzumab
Drug: Recombinant Human Interleukin-2
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2022-01-26

Last Posted Date: 2024-12-12

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 1

Registration Number: NCT05207722

Locations: 🇺🇸
Scripps Health, La Jolla, California, United States
🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Phase 1

Terminated

Conditions: Glioblastoma Multiforme
Analgesics
Peripheral Nervous System Agents
Physiological Effects of Drugs
Analgesics, Non-narcotic
Astrocytoma, Grade IV
Giant Cell Glioblastoma
Cyclophosphamide
Antiviral Agents
Immunosuppressive Agents

First Posted Date: 2020-07-28

Last Posted Date: 2022-08-10

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 3

Registration Number: NCT04489420

Locations: 🇺🇸
The Univeristy of Texas MD ANderson Cancer Center, Houston, Texas, United States

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Phase 1

Conditions: Coronaviridae Infections
Immunologic Disease
Antiviral Agents
Pneumonia
Virus Disease
Anti-infective Agents
Coronavirus Infection
Respiratory Tract Disease
Respiratory Tract Infections
RNA Virus Infections

First Posted Date: 2020-04-28

Last Posted Date: 2022-05-25

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 86

Registration Number: NCT04365101

Locations: 🇺🇸
UC Irvine, Irvine, California, United States
🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸
Scripps Health, San Diego, California, United States

and more 3 locations

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Phase 1

Terminated

Conditions: Leukemia in Remission
Relapsed Adult AML
Neoplasms
Immunosuppressive Agents
Analgesics, Non-narcotic
Anti-infective Agents
Analgesics
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Immunologic Factors

Interventions: Biological: CYNK-001

First Posted Date: 2020-03-17

Last Posted Date: 2024-12-12

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 27

Registration Number: NCT04310592

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 7 locations

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma
Hemostatic Disorder
Cardiovascular Diseases
Hematologic Diseases
Lymphoproliferative Disorders
Physiological Effects of Drugs
Neoplasm, Plasma Cell
Neoplasms
Paraproteinemias
Blood Protein Disorders

First Posted Date: 2020-03-16

Last Posted Date: 2023-02-16

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 29

Registration Number: NCT04309084

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Roswell Park Comprehensive Cancer Institute, Buffalo, New York, United States

and more 1 locations

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: rhIL-2
Biological: PNK-007

First Posted Date: 2016-11-04

Last Posted Date: 2020-07-22

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 15

Registration Number: NCT02955550

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Washington Univ School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 4 locations

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Biological: PNK-007
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Human recombinant Interleukin-2 (rhIL-2)

First Posted Date: 2016-05-24

Last Posted Date: 2020-07-22

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 10

Registration Number: NCT02781467

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 4 locations

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

Phase 2

Completed

Conditions: Diabetic Nephropathies
Peripheral Nervous System Diseases

Interventions: Biological: PDA-002
Drug: Placebo

First Posted Date: 2015-09-17

Last Posted Date: 2022-02-02

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 26

Registration Number: NCT02552277

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC- Southland Neurologic Associates - Los Alamitos, Garden Grove, California, United States
🇺🇸
SDS Clinial Trials, Inc, Orange, California, United States
🇺🇸
Compass Research, LLC, Orlando, Florida, United States

and more 4 locations

Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Phase 2

Withdrawn

Conditions: Diabetic Foot
Peripheral Arterial Disease

Interventions: Drug: Placebo
Drug: PDA-002

First Posted Date: 2015-06-02

Last Posted Date: 2018-03-01

Lead Sponsor: Celularity Incorporated

Registration Number: NCT02460081

Locations: 🇺🇸
University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy